positron emission tomography in clinical oncology chun ki kim, m.d. mount sinai school of medicine...
TRANSCRIPT
![Page 1: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/1.jpg)
Positron Emission Tomography
in Clinical Oncology
Chun Ki Kim, M.D.Chun Ki Kim, M.D.
Mount Sinai School of MedicineMount Sinai School of Medicine
New York, New YorkNew York, New York
![Page 2: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/2.jpg)
![Page 3: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/3.jpg)
![Page 4: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/4.jpg)
Commonly used PET Radiotracers
• [F-18] FDG - Glucose metabolism
• [C-11] Methionine - Amino acid transport- Incorporation of amino acid into protein fractions
• [O-15] Water - Blood flow• [N-13] Ammonia - Blood flow• Rb-82 - Blood flow
![Page 5: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/5.jpg)
• [C-11] Thymidine Tumor cellular proliferation rate• [C-11] Aminoisobutyric acid Tumor amino acid uptake• [F-18] 5-FU Prediction/evaluation of
ChemoTx• [C-11] Tyrosine Tumor metabolism• [N-13] Glutamate Tumor metabolism
• [C-11] Acetate Myocardial oxidative metabolism• [C-11] Palmitate Myocardial fatty acid metabolism
• [F-18] FluoroDOPA Dopamine synthesis• Many other receptor agents Dopamine, serotonin, opiate etc.
Potential PET Radiotracers
![Page 6: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/6.jpg)
PET Radiotracer approved by FDA
• [F-18] FDG (fluoro deoxyglucose)
Malignancy ~ Glucose / FDG uptake
![Page 7: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/7.jpg)
![Page 8: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/8.jpg)
NORMAL TUMOR
• Overexpression of Glucose transporters• Higher levels of Hexokinase• Down-regulation of Glucose-6-phosphatase• Anaerobic glycolysis, less ATP per glucose molecule, more glucose molecules needed for ATP production• General increase in metabolism from high growth rates
![Page 9: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/9.jpg)
Malignancy
Glucose/FDG uptake
![Page 10: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/10.jpg)
Gallium PET
![Page 11: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/11.jpg)
Metastatic Thyroid Ca. to Lung, Mediastinum, and Skeleton
![Page 12: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/12.jpg)
![Page 13: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/13.jpg)
General Indications for FDG-PET Tumor Imaging
DDx: Benign versus Malignant Staging & Restaging Metastatic work up: Rising tumor markers Monitoring treatment response Scar/necrosis/fibrosis vs. Recurrent/residual disease Grading/Prognosis Detection of unknown primary
![Page 14: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/14.jpg)
New Medicare Coverage Policy for FDG PET
• Lung Ca (NSC): Dx, Staging & restaging• Esophgeal Ca: Dx, Staging & restaging• Colorectal Ca: Dx, Staging & restaging• Lymphoma: Dx, Staging & restaging• Melanoma: Dx, Staging & restaging,
Non-covered for evaluating regional nodes• Head & Neck Ca: Dx, Staging & restaging
![Page 15: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/15.jpg)
Lung Cancer
Dx: Solitary Pulmonary NoduleStagingMetastatic work-up
![Page 16: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/16.jpg)
Solitary Pulmonary Nodule
• Incidence detected by CXR: 130,000/year.
50-60%: Benign
20-40%: Invasive nodule biopsy
Resection.
![Page 17: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/17.jpg)
CT: an indeterminant LUL nodule.
![Page 18: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/18.jpg)
![Page 19: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/19.jpg)
Efficacy of PET Solitary Pulmonary Nodule
• Sensitivity = 97%• Specificity = 78%
(Meta-analysis of >40 articles: Gould et al. JAMA 2001)
![Page 20: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/20.jpg)
False Positives:
Active Infection/Inflammation
TB
PneumoniaCryptococcosisHistoplasmosis
AspergillosisInflammatory
![Page 21: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/21.jpg)
Staging
![Page 22: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/22.jpg)
![Page 23: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/23.jpg)
![Page 24: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/24.jpg)
60/M: Lung Ca.
![Page 25: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/25.jpg)
62y/o Lung Ca. with adrenal mass
![Page 26: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/26.jpg)
![Page 27: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/27.jpg)
Colorectal Cancer:Clinical Indications for PET
Imaging Staging before primary resection? Detection of Lesions after Primary Resection
Staging before resection of recurrent disease.Rising CEA in the absence of a known source.Equivocal/residual lesion on conventional imaging.Patient is clinically symptomatic, but CEA is normal.
Monitoring treatment response (pre-op & post-op)
![Page 28: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/28.jpg)
Staging before resection of recurrent disease
![Page 29: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/29.jpg)
63 y/o woman with a H/O Colon Ca. and liver metastases
![Page 30: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/30.jpg)
79/M. Resection of Rectal Ca (Dukes B) 4 mos earlier,
CEA, CT: possible local relapse.
![Page 31: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/31.jpg)
T1 T2
T1 enhanced T1 enhanced
• F/68• H/O Colon Ca.• Rising CEA• CT/MRI;
multiple cysts
![Page 32: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/32.jpg)
Sagittal Transverse Coronal
![Page 33: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/33.jpg)
YW: Colon Ca• 3/00: (-) CT • 5/00: rising CEA
• 6/00: (+) PET
• 7/00: CT
![Page 34: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/34.jpg)
58/M - S/P Colon CaRising CEA
Coronal Coronal Transverse
![Page 35: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/35.jpg)
58/M - S/P Colon CaRising CEA
Local recurrence
Hemangioma
![Page 36: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/36.jpg)
• 48y/o with Colon Ca.• S/P Primary resection.• S/P Resection of liver lesion
• Now with CEA • CT: (-) for mets
![Page 37: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/37.jpg)
• 48y/o with Colon Ca.• S/P Primary resection.• S/P Resection of liver lesion
• Now with CEA • CT: (-) for mets
![Page 38: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/38.jpg)
N. G. 8/15/00Colon cancer with a Hx of UCProven mesenteric carcinomatosis
![Page 39: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/39.jpg)
1756441
![Page 40: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/40.jpg)
Huebner et al. J Nucl Med 2000;41:1177-1189
![Page 41: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/41.jpg)
Huebner et al. J Nucl Med 2000;41:1177-1189
![Page 42: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/42.jpg)
Colorectal Cancer: A possible algorithm
CT evidence of resectable disease in patient suitable for surgery
WholeBodyPET imaging
![Page 43: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/43.jpg)
Colorectal Cancer: A possible algorithm
CT evidence of resectable disease in patient suitable for surgery
WholeBodyPET imaging
Further evaluation of CT abnormality
All sites negative
![Page 44: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/44.jpg)
Colorectal Cancer: A possible algorithm
CT evidence of resectable disease in patient suitable for surgery
WholeBodyPET imaging
Further evaluation of CT abnormality
Surgery
All sites negative
PET = CT and other sites negative
![Page 45: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/45.jpg)
Colorectal Cancer: A possible algorithm
CT evidence of resectable disease in patient suitable for surgery
WholeBodyPET imaging
Further evaluation of CT abnormality
Non-surgical management
Surgery
All sites negative
+ ve at multipleSites
PET = CT and other sites negative
![Page 46: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/46.jpg)
44/F with Colon Ca, S/P primary resection.CT: multiple liver mets and a lung nodule
Treated with systemic chemoTx instead of intra-arterial chemoTx.
Staging:
![Page 47: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/47.jpg)
Colorectal Cancer:Clinical Indications for PET Imaging
Detection of Lesions Staging before resection of recurrent disease. Rising CEA in the absence of a known source. Equivocal/residual lesion on conventional imaging. Patient is clinically symptomatic, but CEA is normal.
Monitoring treatment response (pre-op & post-op) Staging before primary resection?
![Page 48: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/48.jpg)
S/P ChemoRx
![Page 49: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/49.jpg)
Before 2mo after Adjuvant chemo and radioTxPrior to surgery for rectal Ca.
![Page 50: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/50.jpg)
Optimal time to scan after treatment??
Uptake may be seen in inflammatory tissue / macrophages.
Residual FDG activity after treatment:Not always active tumor
• 1 month after Chemo.
PET findings at 1 mo ~ CT findings at 3 mosFindlay et al. J Clin Oncol 1996
• Several months after RT?
![Page 51: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/51.jpg)
Lymphoma: Indications for PET Imaging
Dx Staging Monitoring treatment response Recurrence?
![Page 52: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/52.jpg)
Evaluation of early therapeutic response:
Is treatment effective?FDG uptake represents cell viability.
FDG uptake can be markedly decreased or even completely suppressed after 1 or 2 cycles of chemotherapy
Early determination is important: To avoid the toxicity of ineffective therapy. To allow selection of a new therapeutic regimen.
![Page 53: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/53.jpg)
1846641Lymphoma
Before
After2 cylcles ofChemo
![Page 54: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/54.jpg)
Lymphoma
Before
After2 cylcles ofChemo
![Page 55: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/55.jpg)
56y/o : Lymphoma
![Page 56: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/56.jpg)
Before 1 month after XRT
![Page 57: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/57.jpg)
Esophageal/Gastro-esophageal Cancer:
Clinical Indications for PET Imaging
Pre-op stagingMonitoring treatment responseSuspected recurrence Prognostication
![Page 58: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/58.jpg)
Esophageal/ Gastro-esophageal Cancer:Clinical Indications for PET Imaging
Pre-op stagingCT: Limited sensitivityEUS: More accurate for assessing local
invasion and regional nodal mets.
Limitations: stenosis,
celiac,
right hepatic lobe, peritoneum
![Page 59: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/59.jpg)
(Choi et al: J Nucl Med 2000)
Evaluation of N stage of patients with Esophageal Cancer: 48 patients underwent esohagectomy and lymph node dissection (2 field=35pts, 3 field=13pts)
![Page 60: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/60.jpg)
Evaluation of metastases in Esophageal Cancer: CT versus PET
CT PET
Kole 1998 Lymph nodes 62% 90%Resectability 65% 88%
Choi 2000 Lymph nodes 78% 86%N staging 60% 83%
Luketich 1999 Distant mets 63% 84%
![Page 61: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/61.jpg)
Rt. Paratracheal
Subcarinal
Lt. Gastric
Common hepatic& Celiac
Rt. Paratracheal
Subcarinal
Lt. Gastric
Common hepatic& Celiac
![Page 62: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/62.jpg)
62F: Gastric Ca. S/P ResectionCT: RecurrencePET performed to exclude other sites of tumor
Ultrasound: confirmed a liver metsSurgery cancelled and the patient treated with Chemo
![Page 63: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/63.jpg)
![Page 64: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/64.jpg)
Gastro-esophageal Cancer:Clinical Indications for PET
Imaging
Pre-op stagingMonitoring treatment responseSuspected recurrence Prognostication
![Page 65: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/65.jpg)
Before
sagittal coronal
AfterRadiochemo
49M: large squamous esophageal Ca.Echo-endoscopy – an enlarged node
![Page 66: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/66.jpg)
Gastro-esophageal Cancer:Clinical Indications for PET
Imaging
Pre-op stagingMonitoring treatment responseSuspected recurrencePrognostication
![Page 67: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/67.jpg)
45M: S/P esophagectomy, Patient is clinically asymptomatic alkaline phosphatase
![Page 68: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/68.jpg)
Gastro-esophageal Cancer:Clinical Indications for PET
Imaging
Pre-op stagingMonitoring treatment responseSuspected recurrencePrognostication
![Page 69: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/69.jpg)
Surviavl based on initial PET scan identification of distant versus local disease only: (Luketich et al: Ann Thorac Surg 1999;68)
![Page 70: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/70.jpg)
Pancreatic Cancer:Potential Indications for PET Imaging
DDx: Chronic pancreatic mass vs. Cancer Staging: Nodal mets and liver mets. Monitoring treatment response Prognostication
![Page 71: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/71.jpg)
53/F: Pancreatic mass
![Page 72: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/72.jpg)
51F: CT: (1) Mass forming pancreatitis vs Cancer (2) Hepatic Hemangioma vs Metastasis
Coronal Sagittal
![Page 73: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/73.jpg)
Pancreatic Cancer:DDx: Chronic pancreatic mass vs. Cancer
Delbeke et al: J Nucl Med 1999
![Page 74: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/74.jpg)
Brain Tumor
Grading Prognosis/Survival.Necrosis or Residual disease after
radiation therapy?
![Page 75: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/75.jpg)
High Grade
Low Grade
![Page 76: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/76.jpg)
Kim CK et al. J Neuro-Oncol 1991
![Page 77: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/77.jpg)
![Page 78: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/78.jpg)
Thyroid Cancer Thyroglobulin (+)
Iodine-131 scan (-)
FDG PET scan is useful.
![Page 79: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/79.jpg)
IV
ML
FDG-PET I-131
Anterior Posterior
M
2 Coronal slices
![Page 80: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/80.jpg)
62 y/o male S/P Resection of transglottic right laryngeal cancerR/O Recurrence
![Page 81: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/81.jpg)
FDG PET Imaging
Determination of the site of unknown primary tumor
20~30%
![Page 82: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/82.jpg)
Prediction of tumor response to treatment:
Will the tumor respond to treatment?
Labeled Estrogen [F-18] 5-Fluorouracil (5-FU)
![Page 83: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/83.jpg)
FDG-PET Tumor Imaging
DDx: Is the lesion benign or malignant? Staging:
Re-staging: Evaluation of early therapeutic response: Scar/Necrosis vs recurrent/residual disease after surgery.
Scar/Necrosis vs recurrent/residual disease after XRT. Histologic grading / Prognosis.
Detection of unknown primary.
![Page 84: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/84.jpg)
Summary: PET
• Safe.• Shows all the organ systems of the body with one image.• Decreases the number of diagnostic (imaging) procedures.• Diagnoses disease often before it shows up on other tests.• Shows the progress of disease and how the body responds
to treatment.• Reduces or eliminates ineffective or unnecessary surgical
or medical treatments and hospitalization.• Significantly reduces multiple medical costs and avoids
needless pain to the patient.
![Page 85: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/85.jpg)
The influence of blood glucose levels
on 18FDG uptake in cancer(Crippa et al. Tumori 1997:83:748-752)
8 patients - 20 liver metastases on CT• PET 1: Fasting (92.4±10.2)
All 20 were (+) on PET.
• PET 2: Glucose infusion (158±13.8)6/20 undetected, and 10 lesions localized less clearly.
![Page 86: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/86.jpg)
• 70-years-old female smoker • CT showed Rt mid lung mass and inhomogeneity
throughout the liver
![Page 87: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/87.jpg)
![Page 88: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/88.jpg)
Coronal Sagittal
![Page 89: Positron Emission Tomography in Clinical Oncology Chun Ki Kim, M.D. Mount Sinai School of Medicine New York, New York](https://reader036.vdocuments.us/reader036/viewer/2022062421/56649cc45503460f9498d81e/html5/thumbnails/89.jpg)
55 y/o womanDx’ed with colon ca.S/P resection 2 yrs agoCEA level is risingNo evidence of recurrence. CT: normal.